Advaxis, Inc. (ADXS) Stock Ratings


View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:


Not Rated

No Current Ratings
View All-Time Ratings

Other Member Ratings

View Most Rated Stocks

Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
davetel davetel 10/08/2015 3 months $10.51 $9.59 -8.75% -8 Ended
Comments:
Jammin Jammin 09/30/2015 3 months $10.84 $11.56 +6.64% 6 Ended
Comments:
Drejay Drejay 09/15/2015 1 month $19.20 $9.87 -48.58% 48 Ended
Comments: This has hit my sell price target way before the 3 months on my rating - I am changing to a sell.
UdomLoveTey UdomLoveTey 08/05/2015 3 months $15.36 $12.38 -19.4% 19 Ended
Comments:
DJaxx DJaxx 07/31/2015 3 months $16.66 $12.73 -23.59% 23 Ended
Comments:
itssofluffyimgonnadie itssofluffyimgonnadie 07/07/2015 3 months $18.97 $10.93 -42.38% 42 Ended
Comments:
tpypeman tpypeman 06/17/2015 3 months $22.51 $17.81 -20.88% -20 Ended
Comments: Company has few competitors
lcsol lcsol 06/16/2015 3 months $22.74 $16.51 -27.4% -27 Ended
Comments:
laurvp laurvp 06/09/2015 1 week $24.34 $23.78 -2.3% 2 Ended
Comments:
worldbroker worldbroker 04/17/2015 3 months $19.48 $18.37 -5.7% -5 Ended
Comments: Advaxis nr.1 on Cancer Immunotherapy
Orhan Orhan 04/15/2015 1 month $19.06 $18.97 -0.47% -1 Ended
Comments:
Fizzled Fizzled 04/13/2015 3 months $20.10 $18.58 -7.56% -7 Ended
Comments:
chaosobserver chaosobserver 01/11/2015 1 Year $11.30 $8.09 -28.41% -28 Ended
Comments:
prometheusX prometheusX 04/08/2014 3 months $3.03 $3.12 +2.97% 2 Ended
Comments: too undervalued. gap up to 4-5 possible. expecting news soon
sporter101 sporter101 04/03/2014 3 months $3.12 $3.16 +1.28% 1 Ended
Comments: strong upward potential, awaiting buyout sooner or later

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.